Skip to main content

CanSinoBIO COVID-19 vaccine, tested at lower dosage, safe for children: study

CanSinoBIO’s single-dose COVID-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed.

Researchers decided to lower the dosage after a few participants developed fever and headaches graded at level 2 severity – the second-lowest of four levels. In children, the lower dose triggered higher antibody levels than the dosage approved for use in adults in China, according to the peer-reviewed finding from a mid-stage trial.

The trial recruited 150 children and around 300 adults.

The results also showed that children given one lower dose had a stronger antibody response than adults who were given a booster shot 56 days after the first dose.

But the antibody readings did not show to what extent the vaccine can offer protection against COVID-19, researchers from a Chinese disease control agency, CanSinoBIO and other Chinese institutes cautioned in a paper.

CanSinoBIO’s vaccine has not yet got the greenlight for children. China has approved two vaccines, developed by Sinovac and Sinopharm, for use in children from the age of three but vaccinations have yet to begin for those under 12.

The paper said the booster shot for CanSinoBIO’s vaccine improved antibody responses in participants of different age groups, especially for older adults.

But cellular responses, another important part of human immune system, were not boosted by the second shot and researchers said a wider interval than 56 days should be considered.

 

The post CanSinoBIO COVID-19 vaccine, tested at lower dosage, safe for children: study appeared first on ARY NEWS.



from ScienceTechnology – ARY NEWS https://ift.tt/3u70qs5 https://ift.tt/eA8V8J


from TechCrunch https://ift.tt/3ENKorT
via IFTTT
Labels:

Comments

Post a Comment

Popular posts from this blog

Max Q: Psyche(d)

In this issue: SpaceX launches NASA asteroid mission, news from Relativity Space and more. © 2023 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/h6Kjrde via IFTTT
Post a Comment
Read more

Max Q: Anomalous

Hello and welcome back to Max Q! Last week wasn’t the most successful for spaceflight missions. We’ll get into that a bit more below. In this issue: First up, a botched launch from Virgin Orbit… …followed by one from ABL Space Systems News from Rocket Lab, World View and more Virgin Orbit’s botched launch highlights shaky financial future After Virgin Orbit’s launch failure last Monday, during which the mission experienced an  “anomaly” that prevented the rocket from reaching orbit, I went back over the company’s financials — and things aren’t looking good. For Virgin Orbit, this year has likely been completely turned on its head. The company was aiming for three launches this year, but everything will remain grounded until the cause of the anomaly has been identified and resolved. It’s unclear how long that will take, but likely at least three months. Add this delay to Virgin’s dwindling cash reserves and you have a foundation that’s suddenly much shakier than before. ...
Post a Comment
Read more

What’s Stripe’s deal?

Welcome to  The Interchange ! If you received this in your inbox, thank you for signing up and your vote of confidence. If you’re reading this as a post on our site, sign up  here  so you can receive it directly in the future. Every week, I’ll take a look at the hottest fintech news of the previous week. This will include everything from funding rounds to trends to an analysis of a particular space to hot takes on a particular company or phenomenon. There’s a lot of fintech news out there and it’s my job to stay on top of it — and make sense of it — so you can stay in the know. —  Mary Ann Stripe eyes exit, reportedly tried raising at a lower valuation The big news in fintech this week revolved around payments giant Stripe . On January 26, my Equity Podcast co-host and overall amazingly talented reporter Natasha Mascarenhas and I teamed up to write about how Stripe had set a 12-month deadline for itself to go public, either through a direct listing or by pursuin...
Post a Comment
Read more